{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056286","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.439066+00:00","generated_at":"2026-06-02T06:12:09.099977+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intellia Q1 net loss $107M; cash $953M; Phase 3 enrollment ahead; FDA alignment on ATTRv-PN trial","bullets":["Net loss of $107.4M for Q1 2024; collaboration revenue $28.9M (up from $12.6M YoY) on $21M non-cash adjustment.","Cash and marketable securities $953.4M as of Mar 31, 2024; expected to fund operations into late 2026.","Phase 3 MAGNITUDE trial for ATTR-CM enrolling ahead of projections; over 30 patients dosed, 40+ in screening.","FDA alignment on pivotal Phase 3 design for NTLA-2001 in ATTRv-PN; study of ~50 patients to initiate by year-end.","On track to initiate NTLA-2002 Phase 3 for HAE in H2 2024; Phase 1 long-term data at EAACI June 2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056286","json":"https://secwatch.observer/filing/0000950170-24-056286.json","markdown":"https://secwatch.observer/filing/0000950170-24-056286.md","text":"https://secwatch.observer/filing/0000950170-24-056286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/0000950170-24-056286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/ntla-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:12:09.099977+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fb9e984c15ff410e667427e66c40eecc5a1d465","claim":"Intellia Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024056286/0000950170-24-056286-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}